Cytokinetics Inc (NAS:CYTK)
$ 48.59 -0.39 (-0.8%) Market Cap: 5.09 Bil Enterprise Value: 5.27 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 43/100

Cytokinetics Inc to Discuss Positive Topline Results of Redwood-HCM Call Transcript

Jul 19, 2021 / 12:30PM GMT
Release Date Price: $27 (+40.41%)
Operator

Good morning, and welcome, ladies and gentlemen, to Cytokinetics conference call announcing the top line results of REDWOOD-HCM. (Operator Instructions) I will now turn the call over to Diane Weiser, Cytokinetics Senior Vice President of Corporate Communications and Investor Relations. Please go ahead.

Diane Weiser
Cytokinetics, Incorporated - SVP of Corporate Communications & IR

Welcome, everyone, and thanks for joining us on our call today, which will focus on the top line results of REDWOOD-HCM, the Phase II clinical trial of CK-274, our next-in-class cardiac myosin inhibitor.

Robert Blum, our President and Chief Executive Officer, will begin with an overview of today's announcement. Then Fady Malik, our Executive Vice President of R&D, will present the top line results and our planned next steps in the development program for CK-274. Robert will then provide closing remarks before we open the call to questions.

Please note that portions of the following discussion, including our responses to questions, contain statements that

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot